|
|
| Home | Featured Companies | Virtual Trading Game | Stock Market Blogs | Financial Tools | Investment | Sign Up & Play For Free | |
| Atherogenics, Inc. | |
||||||||||||||||||||||||||||||||||||||||||||||||||||
| FREE SMALLCAP NEWSLETTER STARTING SOON - Sign Up Now | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Atherogenics, Inc. | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AGIX | Last: $0.61 ($-0.03) | Volume: 737,936 | Last Trade: 5/16/2008 4:30:01 PM | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Today
Today | Last 7 Days | 1 Month | 3 Month | 6 Month | 1 Year |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
| Atherogenics, Inc. Profile | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| AtheroGenics is a research-based pharmaceutical company focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including coronary heart disease, organ transplant rejection, rheumatoid arthritis and asthma. Co. has developed a proprietary vascular protectant, or v-protectant , technology platform to discover drugs to treat these types of diseases. Based on its v-protectant platform, Co. has two drug development programs in clinical trials, AGI-1067 and AGI-1096 and is pursuing a number of other preclinical programs. | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Atherogenics, Inc. News & Press Releases | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Semi-Annual Changes to the NASDAQ Biotechnology Index NEW YORK, May 9, 2008 (PRIME NEWSWIRE) -- The NASDAQ OMX Group, Inc. ("NASDAQ") ( NDAQ ) announced today the results of the semi-annual re-ranking of the NASDAQ Biotechnology Index(r) ( NBI ), which will become effective with the market open on M... [more] BUYINS.NET: IRE, LFC, RHD, AGIX, AMGI, CEDU Have Also Been Added ... Insurance News Net (press release): BUYINS.NET: IRE, LFC, RHD, AGIX, AMGI, CEDU Have Also Been Added ... , PA - Mar 14, 2008 AtheroGenics Inc. ( NASDAQ: AGIX ) engages in the discovery, development, and commercialization of drugs for the treatment of chronic inflammato AtheroGenics to Present at Lehman Brothers Global Healthcare ... StreetInsider.com (subscription): (MARKET WIRE) -- 03/11/08 -- AtheroGenics, Inc. ( NASDAQ: AGIX ), a pharmaceutical company focused on the treatment of chronic inflammatory ... AtheroGenics Regains Compliance With NASDAQ Listing Requirement PR-USA.net (press release): AtheroGenics Regains Compliance With NASDAQ Listing Requirement , Bulgaria - Mar 8, 2008 AtheroGenics, Inc. ( NASDAQ : AGIX ), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced that th Unusual 11 Mid-Day Movers 3/4: STEN, LF, PRAN, FINL Higher; TSRA ... StreetInsider.com (subscription): Unusual 11 Mid-Day Movers 3/4: STEN, LF, PRAN, FINL Higher; TSRA ... , MI - Mar 4, 2008 Atherogenics ( Nasdaq: AGIX ) 14.4% HIGHER; NASDAQ today announced that the Company has regained compliance with its Listing Qualifications Panel. Businessnetwire.us: Stock News You Can Use: ASWRF, AGIX, TLPE Trading Markets (press release): , CA - Mar 4, 2008 AtheroGenics, Inc. ( NASDAQ: AGIX ), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, announced earlier today that the ... AtheroGenics Reports First Quarter 2007 Financial Results Genetic Engineering News (press release): AtheroGenics, Inc. ( NASDAQ: AGIX ), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today reported financial results for ... Atlanta’s AtheroGenics drops AstraZeneca deal TechJournal South: ALPHARETTA, GA—AtheroGenics ( NASDAQ:AGIX ) and AstraZeneca are ending their collaboration to develop and commercialize heart drug AGI-1067 after lackluster ... Onyx Pharma: Risky business Blogging Stocks: - Apr 2, 2007 Heart pharma company AtheroGenics Inc ( NASDAQ:AGIX ) watched its stock go down 72%, making it the second worst performer on the NASDAQ. ... AtheroGenics ARISE Trial Results For AGI-1067 Full Study Fail To ... WebWire (press release): AtheroGenics ARISE Trial Results For AGI-1067 Full Study Fail To ... , GA - 5 hours ago AtheroGenics, Inc. ( NASDAQ: AGIX ) today announced that its ARISE Phase III clinical study of its lead drug candidate, AGI-1067, did not show a di On The Move For Thursday, March 22 Forbes: , NY - 6 hours ago Shares of AtheroGenics ( nasdaq: AGIX - news - people ) are on the rise, but it’s still recovering lost ground from its sell-off earlier this week. ... Know Your Drug Stock ABCs: Part 3 Motley Fool: - 3 hours ago For example, tiny specialty pharmaceutical developer AtheroGenics ( Nasdaq: AGIX ) started 2006 with $183 million on hand. By the end of its fiscal fourth ... Waiting on AtheroGenics Motley Fool: - 19 hours ago Undoubtedly one of the biggest winners or losers in this space this year is going to be drugmaker AtheroGenics ( Nasdaq: AGIX ) when it releases phase 3 study ... AtheroGenics Announces Promotion of Charles A. Deignan to Vice ... Genetic Engineering News (press release): AtheroGenics Announces Promotion of Charles A. Deignan to Vice ... , NY - 10 hours ago AtheroGenics, Inc. ( NASDAQ: AGIX ), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced that Charle CybeRelease: (OTC: APPI) Receives New Price Target WebWire (press release): ... FuelCell Energy, Inc. (Nasdaq: FCEL), Sify Limited (Nasdaq: SIFY), Alvarion Ltd. (Nasdaq: ALVR), AtheroGenics, Inc. ( Nasdaq: AGIX ) and Optimal Group, ... AtheroGenics (AGIX) option implied volatility Elevated into Data StreetInsider.com (subscription): , MI - Feb 1, 2007 AtheroGenics ( Nasdaq: AGIX ) : AGIX focuses on the discovery, development and commercialization of novel drugs for ... StreetInsider.com provides ... Daily option update-January 30, 2007 Daily option update - January 30, 2007 - Blogging Stocks: Daily option update - January 30, 2007 Blogging Stocks - Jan 30, 2007 AtheroGenics Inc. ( NASDAQ:AGIX ) derivatives high risk, option volume up traders prepare for data. AtheroGenics focuses on the discovery, development and ... Matthew Herper On Health Care Forbes: , NY - Dec 21, 2006 ... One competitor to torcetrapib was a pill aimed at preventing heart attacks, under development by AtheroGenics ( nasdaq : AGIX - news - people ) and partner ... Zacks Analyst Blog Highlights: AtheroGenics, DRS Technologies and ... Business Wire (press release): Zacks Analyst Blog Highlights: AtheroGenics, DRS Technologies and ... , CA - Dec 20, 2006 ... Stocks recently featured in the blog include: AtheroGenics ( Nasdaq : AGIX ), DRS Technologies (NYSE: DRS) and CoBiz (Nasdaq: COBZ). ... CybeRelease: TheCapitalReport.com Issues (OTC: HYPF) Investor Alert WebWire (press release): , GA - Dec 11, 2006 CybeRelease Decliners are NeoPharm, Inc. (Nasdaq: NEOL), AtheroGenics, Inc. ( Nasdaq: AGIX ), Leadis Technology, Inc. (Nasdaq: LDIS), Northfield Laboratories ... CybeRelease: TheCapitalReport.com Issues (OTC: HYPF) Investor ... WebWire (press release): ... Inc. (Nasdaq: NEOL), AtheroGenics, Inc. ( Nasdaq : AGIX ), Leadis Technology, Inc. (Nasdaq: LDIS), Northfield Laboratories Inc. (Nasdaq ... AtheroGenics (AGIX) April option implied volatility Elevated into ... StreetInsider.com (subscription): AtheroGenics (AGIX) April option implied volatility Elevated into ... , MI - Dec 1, 2006 AtheroGenics ( Nasdaq : AGIX ) : AGIX focuses on the discovery, development and commercialization of novel drugs for the treatment of chronic inf AtheroGenics to Present at the Lazard Capital Markets Third Annual ... Genetic Engineering News (press release): AtheroGenics to Present at the Lazard Capital Markets Third Annual ... , NY - Nov 21, 2006 AtheroGenics, Inc. ( NASDAQ : AGIX ), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, announced today that AtheroGenics and AstraZeneca Win Best Partnership Alliance of the ... Genetic Engineering News (press release): AtheroGenics and AstraZeneca Win Best Partnership Alliance of the ... , NY - Nov 16, 2006 AtheroGenics, Inc. ( NASDAQ : AGIX ), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced winnin AtheroGenics Announces Key Additions to Regulatory Affairs Team Genetic Engineering News (press release): , NY - Nov 7, 2006 AtheroGenics, Inc. ( NASDAQ : AGIX ), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced that it named J ... Playing the AtheroGenics Waiting Game Motley Fool: - Oct 24, 2006... AtheroGenics (Nasdaq: AGIX) is one such small biotech, and the company's announcement of phase 3 trial results early next year for its lead product, AGI-1067 ... AtheroGenics (AGIX) Top Q3 EPS by 14c, Guides Above StreetInsider.com (subscription): , MI - Oct 24, 2006AtheroGenics, Inc. (NASDAQ: AGIX) reports a Q3 loss of $0.36, 14 cents better than estimates. Revenues were $10.3 million vs. $6.26 million consensus. ... AtheroGenics continues improvement in Q3 Atlanta Business Chronicle: , GA - Oct 24, 2006The Atlanta-based drug developer (NASDAQ: AGIX) had a net loss of $14.4 million on $10.3 million in revenue in the third quarter, compared with a net loss of ... AtheroGenics Reports Third Quarter 2006 Financial Results CCNMatthews (press release): (CCNMatthews - October 24, 2006) - AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory ... AtheroGenics to Webcast Third Quarter Results Conference Call on ... Genetic Engineering News (press release): , NY - Oct 12, 2006AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced that it expects to ... AtheroGenics (AGIX) April option implied volatility Elevated at ... StreetInsider.com (subscription): , MI - Sep 27, 2006AtheroGenics (Nasdaq: AGIX) : AGIX focuses on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases ... |
|||||||||||||||||||||||||||||||||||||||||||||||||||||
| Home | Companies | Game | Blogs | Savings Calculator | Tools | Contact Us | Disclosure | Site Map | Sign Up | Copyright © 2008 SmallCapWatch, LLC. |
| Never invest based soley on information from this website or our e-mail and IM alerts | |
